Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Tai Tien Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Canagliflozin (TA-7284) has Been Approved in Taiwan For Diabetic Nephropathy
Details : Tai Tien Pharmaceuticals has obtained the regulatory approval of CANAGLU® (CANAGLU)(INN: canagliflozin; Japan names: CANAGLU® Tablets 100mg) for a treatment agent for diabetic nephropathy in Taiwan FDA.
Product Name : Canaglu
Product Type : HPAPI
Upfront Cash : Inapplicable
February 26, 2021
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Tai Tien Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable